Cargando…

Independent risk factors for myasthenic crisis and disease exacerbation in a retrospective cohort of myasthenia gravis patients

BACKGROUND: Myasthenic crisis (MC) and disease exacerbation in myasthenia gravis (MG) are associated with significant lethality and continue to impose a high disease burden on affected patients. Therefore, we sought to determine potential predictors for MC and exacerbation as well as to identify fac...

Descripción completa

Detalles Bibliográficos
Autores principales: Nelke, Christopher, Stascheit, Frauke, Eckert, Carmen, Pawlitzki, Marc, Schroeter, Christina B., Huntemann, Niklas, Mergenthaler, Philipp, Arat, Ercan, Öztürk, Menekse, Foell, Dirk, Schreiber, Stefanie, Vielhaber, Stefan, Gassa, Asmae, Stetefeld, Henning, Schroeter, Michael, Berger, Benjamin, Totzeck, Andreas, Hagenacker, Tim, Meuth, Sven G., Meisel, Andreas, Wiendl, Heinz, Ruck, Tobias
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9005160/
https://www.ncbi.nlm.nih.gov/pubmed/35413850
http://dx.doi.org/10.1186/s12974-022-02448-4
_version_ 1784686397170384896
author Nelke, Christopher
Stascheit, Frauke
Eckert, Carmen
Pawlitzki, Marc
Schroeter, Christina B.
Huntemann, Niklas
Mergenthaler, Philipp
Arat, Ercan
Öztürk, Menekse
Foell, Dirk
Schreiber, Stefanie
Vielhaber, Stefan
Gassa, Asmae
Stetefeld, Henning
Schroeter, Michael
Berger, Benjamin
Totzeck, Andreas
Hagenacker, Tim
Meuth, Sven G.
Meisel, Andreas
Wiendl, Heinz
Ruck, Tobias
author_facet Nelke, Christopher
Stascheit, Frauke
Eckert, Carmen
Pawlitzki, Marc
Schroeter, Christina B.
Huntemann, Niklas
Mergenthaler, Philipp
Arat, Ercan
Öztürk, Menekse
Foell, Dirk
Schreiber, Stefanie
Vielhaber, Stefan
Gassa, Asmae
Stetefeld, Henning
Schroeter, Michael
Berger, Benjamin
Totzeck, Andreas
Hagenacker, Tim
Meuth, Sven G.
Meisel, Andreas
Wiendl, Heinz
Ruck, Tobias
author_sort Nelke, Christopher
collection PubMed
description BACKGROUND: Myasthenic crisis (MC) and disease exacerbation in myasthenia gravis (MG) are associated with significant lethality and continue to impose a high disease burden on affected patients. Therefore, we sought to determine potential predictors for MC and exacerbation as well as to identify factors affecting outcome. METHODS: We examined a retrospective, observational cohort study of patients diagnosed with MG between 2000 and 2021 with a mean follow-up of 62.6 months after diagnosis from eight tertiary hospitals in Germany. A multivariate Cox regression model with follow-up duration as the time variable was used to determine independent risk factors for MC and disease exacerbation. RESULTS: 815 patients diagnosed with MG according to national guidelines were included. Disease severity at diagnosis (quantitative MG score or Myasthenia Gravis Foundation of America class), the presence of thymoma and anti-muscle specific tyrosine kinase-antibodies were independent predictors of MC or disease exacerbation. Patients with minimal manifestation status 12 months after diagnosis had a lower risk of MC and disease exacerbation than those without. The timespan between diagnosis and the start of immunosuppressive therapy did not affect risk. Patients with a worse outcome of MC were older, had higher MGFA class before MC and at admission, and had lower vital capacity before and at admission. The number of comorbidities, requirement for intubation, prolonged mechanical ventilation, and MC triggered by infection were associated with worse outcome. No differences between outcomes were observed comparing treatments with IVIG (intravenous immunoglobulin) vs. plasma exchange vs. IVIG together with plasma exchange. CONCLUSIONS: MC and disease exacerbations inflict a substantial burden of disease on MG patients. Disease severity at diagnosis and antibody status predicted the occurrence of MC and disease exacerbation. Intensified monitoring with emphasis on the prevention of infectious complications could be of value to prevent uncontrolled disease in MG patients. GRAPHICAL ABSTRACT: [Image: see text] SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12974-022-02448-4.
format Online
Article
Text
id pubmed-9005160
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-90051602022-04-13 Independent risk factors for myasthenic crisis and disease exacerbation in a retrospective cohort of myasthenia gravis patients Nelke, Christopher Stascheit, Frauke Eckert, Carmen Pawlitzki, Marc Schroeter, Christina B. Huntemann, Niklas Mergenthaler, Philipp Arat, Ercan Öztürk, Menekse Foell, Dirk Schreiber, Stefanie Vielhaber, Stefan Gassa, Asmae Stetefeld, Henning Schroeter, Michael Berger, Benjamin Totzeck, Andreas Hagenacker, Tim Meuth, Sven G. Meisel, Andreas Wiendl, Heinz Ruck, Tobias J Neuroinflammation Research BACKGROUND: Myasthenic crisis (MC) and disease exacerbation in myasthenia gravis (MG) are associated with significant lethality and continue to impose a high disease burden on affected patients. Therefore, we sought to determine potential predictors for MC and exacerbation as well as to identify factors affecting outcome. METHODS: We examined a retrospective, observational cohort study of patients diagnosed with MG between 2000 and 2021 with a mean follow-up of 62.6 months after diagnosis from eight tertiary hospitals in Germany. A multivariate Cox regression model with follow-up duration as the time variable was used to determine independent risk factors for MC and disease exacerbation. RESULTS: 815 patients diagnosed with MG according to national guidelines were included. Disease severity at diagnosis (quantitative MG score or Myasthenia Gravis Foundation of America class), the presence of thymoma and anti-muscle specific tyrosine kinase-antibodies were independent predictors of MC or disease exacerbation. Patients with minimal manifestation status 12 months after diagnosis had a lower risk of MC and disease exacerbation than those without. The timespan between diagnosis and the start of immunosuppressive therapy did not affect risk. Patients with a worse outcome of MC were older, had higher MGFA class before MC and at admission, and had lower vital capacity before and at admission. The number of comorbidities, requirement for intubation, prolonged mechanical ventilation, and MC triggered by infection were associated with worse outcome. No differences between outcomes were observed comparing treatments with IVIG (intravenous immunoglobulin) vs. plasma exchange vs. IVIG together with plasma exchange. CONCLUSIONS: MC and disease exacerbations inflict a substantial burden of disease on MG patients. Disease severity at diagnosis and antibody status predicted the occurrence of MC and disease exacerbation. Intensified monitoring with emphasis on the prevention of infectious complications could be of value to prevent uncontrolled disease in MG patients. GRAPHICAL ABSTRACT: [Image: see text] SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12974-022-02448-4. BioMed Central 2022-04-12 /pmc/articles/PMC9005160/ /pubmed/35413850 http://dx.doi.org/10.1186/s12974-022-02448-4 Text en © The Author(s) 2022 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Research
Nelke, Christopher
Stascheit, Frauke
Eckert, Carmen
Pawlitzki, Marc
Schroeter, Christina B.
Huntemann, Niklas
Mergenthaler, Philipp
Arat, Ercan
Öztürk, Menekse
Foell, Dirk
Schreiber, Stefanie
Vielhaber, Stefan
Gassa, Asmae
Stetefeld, Henning
Schroeter, Michael
Berger, Benjamin
Totzeck, Andreas
Hagenacker, Tim
Meuth, Sven G.
Meisel, Andreas
Wiendl, Heinz
Ruck, Tobias
Independent risk factors for myasthenic crisis and disease exacerbation in a retrospective cohort of myasthenia gravis patients
title Independent risk factors for myasthenic crisis and disease exacerbation in a retrospective cohort of myasthenia gravis patients
title_full Independent risk factors for myasthenic crisis and disease exacerbation in a retrospective cohort of myasthenia gravis patients
title_fullStr Independent risk factors for myasthenic crisis and disease exacerbation in a retrospective cohort of myasthenia gravis patients
title_full_unstemmed Independent risk factors for myasthenic crisis and disease exacerbation in a retrospective cohort of myasthenia gravis patients
title_short Independent risk factors for myasthenic crisis and disease exacerbation in a retrospective cohort of myasthenia gravis patients
title_sort independent risk factors for myasthenic crisis and disease exacerbation in a retrospective cohort of myasthenia gravis patients
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9005160/
https://www.ncbi.nlm.nih.gov/pubmed/35413850
http://dx.doi.org/10.1186/s12974-022-02448-4
work_keys_str_mv AT nelkechristopher independentriskfactorsformyastheniccrisisanddiseaseexacerbationinaretrospectivecohortofmyastheniagravispatients
AT stascheitfrauke independentriskfactorsformyastheniccrisisanddiseaseexacerbationinaretrospectivecohortofmyastheniagravispatients
AT eckertcarmen independentriskfactorsformyastheniccrisisanddiseaseexacerbationinaretrospectivecohortofmyastheniagravispatients
AT pawlitzkimarc independentriskfactorsformyastheniccrisisanddiseaseexacerbationinaretrospectivecohortofmyastheniagravispatients
AT schroeterchristinab independentriskfactorsformyastheniccrisisanddiseaseexacerbationinaretrospectivecohortofmyastheniagravispatients
AT huntemannniklas independentriskfactorsformyastheniccrisisanddiseaseexacerbationinaretrospectivecohortofmyastheniagravispatients
AT mergenthalerphilipp independentriskfactorsformyastheniccrisisanddiseaseexacerbationinaretrospectivecohortofmyastheniagravispatients
AT aratercan independentriskfactorsformyastheniccrisisanddiseaseexacerbationinaretrospectivecohortofmyastheniagravispatients
AT ozturkmenekse independentriskfactorsformyastheniccrisisanddiseaseexacerbationinaretrospectivecohortofmyastheniagravispatients
AT foelldirk independentriskfactorsformyastheniccrisisanddiseaseexacerbationinaretrospectivecohortofmyastheniagravispatients
AT schreiberstefanie independentriskfactorsformyastheniccrisisanddiseaseexacerbationinaretrospectivecohortofmyastheniagravispatients
AT vielhaberstefan independentriskfactorsformyastheniccrisisanddiseaseexacerbationinaretrospectivecohortofmyastheniagravispatients
AT gassaasmae independentriskfactorsformyastheniccrisisanddiseaseexacerbationinaretrospectivecohortofmyastheniagravispatients
AT stetefeldhenning independentriskfactorsformyastheniccrisisanddiseaseexacerbationinaretrospectivecohortofmyastheniagravispatients
AT schroetermichael independentriskfactorsformyastheniccrisisanddiseaseexacerbationinaretrospectivecohortofmyastheniagravispatients
AT bergerbenjamin independentriskfactorsformyastheniccrisisanddiseaseexacerbationinaretrospectivecohortofmyastheniagravispatients
AT totzeckandreas independentriskfactorsformyastheniccrisisanddiseaseexacerbationinaretrospectivecohortofmyastheniagravispatients
AT hagenackertim independentriskfactorsformyastheniccrisisanddiseaseexacerbationinaretrospectivecohortofmyastheniagravispatients
AT meuthsveng independentriskfactorsformyastheniccrisisanddiseaseexacerbationinaretrospectivecohortofmyastheniagravispatients
AT meiselandreas independentriskfactorsformyastheniccrisisanddiseaseexacerbationinaretrospectivecohortofmyastheniagravispatients
AT wiendlheinz independentriskfactorsformyastheniccrisisanddiseaseexacerbationinaretrospectivecohortofmyastheniagravispatients
AT rucktobias independentriskfactorsformyastheniccrisisanddiseaseexacerbationinaretrospectivecohortofmyastheniagravispatients